



ASX Announcement and Media Release

10 February, 2017

SciGen Ltd

CHANGES IN THE BOARD

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce major changes in the Board.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS

SciGen is pleased to announce the appointment of 2 Non-Executive Directors -

Dr. Ju bo Liu

Dr. Ju bo Liu is the President of the Managing Board of Bioton SA. Dr. Liu is the founder and has served as the CEO of Cogenes Biotechnology Incorporation (focused on In vitro diagnosis R&D, manufacturing and marketing) since August 2011 and is the founder and CEO of NovoTek Pharmaceuticals Limited (Hong Kong) and Beijing NovoTek Medicinal Technology Development Co. Ltd (Beijing) (international platform to globalise healthcare products both from within and outside of China) since August 2009. From April 2008 to July 2009 he was the China Chief Representative of Immtech Pharmaceuticals Inc. (US New York) (establishing Chinese activity infrastructure and investment plans). From November 2007 to April 2008, he acted as a Clinical Trial Liaison with US-based Pharmaceuticals Inc. (US New York) carrying out global clinical trial operations in China. From October 2006 to November 2007 he was a scientist at Boston Vertex Pharmaceuticals Inc. (formulation and drug delivery). From July of 2005 to January of 2007 he was as a cofounder and served as the Director of Business Development of JCS Biopolytech Incorporation (modified biopolymer R&D and marketing used for drug delivery and nanotechnology). From August 1997 to February 2001, he served as the Director of Marketing and Regulatory Affairs for Huayuanlong Medicinal Technology Development Co. Ltd. of Beijing, China. Dr. Liu obtained his Bachelor's Degree in Pharmacy from the Department of Pharmacy of the Pharmaceutical University of Shenyang and a Ph.D. from the Department of Pharmaceutical Sciences at the University of Toronto. Furthermore, Dr. Liu is an author or co-author of several publications regarding medical and biological issues.

Mr. Vaidyanathan Viswanath

Mr. Viswanath is a post-graduate in Pharmacology with over 30 years' experience in sales,

marketing, business development and strategic planning in the pharmaceutical Industry across Asia. His previous experience includes Serum Institute - India and Astra - India both in sales and marketing, 8 years with Pharmacia - India and China. Upon completion of the global acquisition of Pharmacia by Pfizer in April 2003, he assumed the position of Director - Business Development & Strategic Planning for Capsugel (a division of Pfizer) based in Bangkok until 2011. Currently living in Beijing, Mr.Viswanath is an Independent Consultant for a number of pharmaceutical companies and in this role offers his expertise in the area of Strategic Marketing, Business Development, Marketing and Sales Effectiveness, Alliance Management, KOL & Advocacy development. With his deep understanding of the trends in the industry backed up by his strong networking capabilities, Mr. Viswanath envisions to act as a bridge for these companies to reach out to companies overseas and vice versa. Mr Viswanath serves on Novotek's Advisory board since 2012.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
--	---------

Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Adam Polonek SciGen Ltd +65 6779 6638
--	---